Fennec Pharmaceuticals Inc.
FENC Nasdaq
SEC CIK 1211583
Follow Fennec Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$19.6M
+57.3% vs same quarter last year
Net income
$4.6M
+827.3% vs same quarter last year
EPS, diluted
$0.12
+700% vs same quarter last year
Operating cash flow
$6.7M
+347.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $44.6M | −$9.7B |
| FY24 | $47.5M | −$436M |
| FY23 | $21.3M | −$16B |
| FY22 | $1.5M | −$23.7M |
| FY21 | - | −$17.3M |
| FY20 | $200K | −$18.1M |
| FY19 | $0 | −$12.8M |
| FY18 | $0 | −$9.9M |
| FY17 | $0 | −$7M |
| FY16 | $0 | −$2.8M |
| FY15 | $0 | −$659K |
| FY14 | $0 | −$2.2M |
| FY13 | $0 | $1.8M |
| FY12 | $0 | −$5.2M |
| FY11 | $0 | $4.7M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −14.1% | −21820.3% |
| FY24 | 5.4% | −917.2% |
| FY23 | −60.1% | −75498.8% |
| FY22 | −1471.6% | −1544.9% |
| FY21 | - | - |
| FY20 | −8942.5% | −9054.5% |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | - | - |
| FY11 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | −$2.2M |
| FY12 | −$3M |
| FY11 | −$3.2M |
- Fennec Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Fennec Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −21820.3% | −30.6% |
| FY24 | −917.2% | −47% |
| FY23 | −75498.8% | −58% |
| FY22 | −1544.9% | −80.4% |
| FY21 | - | −71.8% |
| FY20 | −9054.5% | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |